Long-Term PF-06651600 for the Treatment of Alopecia Areata

Back to Search
Print
Bookmark Trial

NCT04006457

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alopecia Areata
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

for de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:

- Clinical diagnosis of alopecia areata (AA) with no other cause of hair loss. Androgenetic alopecia coexistent with AA is allowed.

- >=25% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis

- No evidence of terminal scalp hair regrowth within 6 months

- Current episode of terminal scalp hair loss <=10 years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

for de novo participants and participants from Study B7931005 and
B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:


- Other types of diseases that can cause hair loss or that could interfere with
assessment of hair loss/regrowth


- Participants with shaved heads must not enter the study until hair has grown back & is
considered stable by the investigator


All participants:


- Participants who have previously taken Janus kinase (JAK) inhibitors other than
PF-06651600 must have received the last dose >12 weeks prior to the screening visit

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Alopecia AreataTopical Crisaborole in Patients With Alopecia Areata
NCT04299503
  1. Boston, Massachusetts
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Alopecia AreataPLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
NCT04517864
  1. Huntington Beach, California
  2. Boca Raton, Florida
  3. Hollywood, Florida
  4. Jacksonville, Florida
  5. Jacksonville, Florida
  6. Miami, Florida
  7. Miramar, Florida
  8. Plantation, Florida
  9. Raleigh, North Carolina
  10. Houston, Texas
  11. Lynchburg, Virginia
  12. Markham, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Alopecia AreataLong-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
  1. New York, New York
  2. San Antonio, Texas
  3. Medellin, Antioquia
  4. Praha 8,
  5. Debrecen,
  6. Bialystok,
  7. Osielsko,
  8. Wroclaw,
  9. Wroclaw,
  10. Madrid,
  11. Valencia,
  12. Birmingham, Alabama
  13. Beverly Hills, California
  14. Irvine, California
  15. Murrieta, California
  16. San Francisco, California
  17. San Francisco, California
  18. Santa Ana, California
  19. Aurora, Colorado
  20. Aurora, Colorado
  21. New Haven, Connecticut
  22. New Haven, Connecticut
  23. New Haven, Connecticut
  24. Washington, District of Columbia
  25. Washington, District of Columbia
  26. Washington, District of Columbia
  27. Washington, District of Columbia
  28. Washington, District of Columbia
  29. Boynton Beach, Florida
  30. Orange Park, Florida
  31. Tampa, Florida
  32. Meridian, Idaho
  33. Chicago, Illinois
  34. Chicago, Illinois
  35. Chicago, Illinois
  36. Chicago, Illinois
  37. Chicago, Illinois
  38. Oakbrook Terrace, Illinois
  39. Skokie, Illinois
  40. Springfield, Illinois
  41. Indianapolis, Indiana
  42. Iowa City, Iowa
  43. Chevy Chase, Maryland
  44. Boston, Massachusetts
  45. Minneapolis, Minnesota
  46. Minneapolis, Minnesota
  47. Omaha, Nebraska
  48. Verona, New Jersey
  49. New York, New York
  50. New York, New York
  51. New York, New York
  52. New York, New York
  53. Chapel Hill, North Carolina
  54. Chapel Hill, North Carolina
  55. Chapel Hill, North Carolina
  56. Cleveland, Ohio
  57. Tulsa, Oklahoma
  58. Portland, Oregon
  59. Houston, Texas
  60. Vienna, Virginia
  61. Caba,
  62. Caba,
  63. Caba,
  64. Kogarah, New South Wales
  65. Kogarah, New South Wales
  66. Benowa, Queensland
  67. Woolloongabba, Queensland
  68. Carlton, Victoria
  69. East Melbourne, Victoria
  70. Parkville, Victoria
  71. Parkville, Victoria
  72. Winnipeg, Manitoba
  73. London, Ontario
  74. Markham, Ontario
  75. Oakville, Ontario
  76. Peterborough, Ontario
  77. Richmond Hill, Ontario
  78. Sudbury, Ontario
  79. Sudbury, Ontario
  80. Toronto, Ontario
  81. Montreal, Quebec
  82. Quebec,
  83. Santiago, LAS Condes
  84. Santiago, Recoleta
  85. Vina del Mar, Valparaiso
  86. Santiago, Vitacura
  87. Medellin, Antioquia
  88. Bogota D.C.,
  89. Nachod,
  90. Praha 10,
  91. Praha 1,
  92. Bad Bentheim,
  93. Berlin,
  94. Budapest,
  95. Gyongyos,
  96. Nagoya, Aichi
  97. Sendai, Miyagi
  98. Osaka-City, Osaka
  99. Hamamatsu, Shizuoka
  100. Koto-ku, Tokyo
  101. Mitaka-shi, Tokyo
  102. Tokyo,
  103. Busan,
  104. Seoul,
  105. Seoul,
  106. Monterrey, Nuevo LEON
  107. Veracruz,
  108. Veracruz,
  109. Grodzisk Mazowiecki,
  110. Krakow,
  111. Lodz,
  112. Ostrowiec Swietokrzyski,
  113. Szczecin,
  114. Warszawa,
  115. Warszawa,
  116. Warszawa,
  117. Warszawa,
  118. Wroclaw,
  119. Wroclaw,
  120. Chelyabinsk,
  121. Kirov,
  122. Moscow,
  123. Moscow,
  124. Rostov-on-Don,
  125. Saint Petersburg,,
  126. Saint Petersburg,
  127. Saint Petersburg,
  128. Yaroslavl,
  129. Badalona, Barcelona
  130. Barcelona,
  131. Cordoba,
  132. Madrid,
  133. Taichung, R.o.c.
  134. Kaohsiung City,
  135. Kaohsiung,
  136. New Taipei City,
  137. Taipei,
  138. Taoyuan City,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Alopecia AreataPF-06651600 for the Treatment of Alopecia Areata
NCT03732807
  1. Beverly Hills, California
  2. Richmond Hill, Ontario
  3. Birmingham, Alabama
  4. Irvine, California
  5. Murrieta, California
  6. San Francisco, California
  7. San Francisco, California
  8. Santa Ana, California
  9. Aurora, Colorado
  10. New Haven, Connecticut
  11. New Haven, Connecticut
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. Washington, District of Columbia
  15. Washington, District of Columbia
  16. Washington, District of Columbia
  17. Boynton Beach, Florida
  18. Orange Park, Florida
  19. Tampa, Florida
  20. Meridian, Idaho
  21. Chicago, Illinois
  22. Chicago, Illinois
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Skokie, Illinois
  26. Springfield, Illinois
  27. Indianapolis, Indiana
  28. Iowa City, Iowa
  29. Iowa City, Iowa
  30. Chevy Chase, Maryland
  31. Boston, Massachusetts
  32. Minneapolis, Minnesota
  33. Minneapolis, Minnesota
  34. Omaha, Nebraska
  35. Verona, New Jersey
  36. New York, New York
  37. New York, New York
  38. New York, New York
  39. New York, New York
  40. Chapel Hill, North Carolina
  41. Chapel Hill, North Carolina
  42. Chapel Hill, North Carolina
  43. Cleveland, Ohio
  44. Tulsa, Oklahoma
  45. Houston, Texas
  46. Caba,
  47. Caba,
  48. Kogarah, New South Wales
  49. Kogarah, New South Wales
  50. Benowa, Queensland
  51. Woolloongabba, Queensland
  52. Carlton, Victoria
  53. East Melbourne, Victoria
  54. Parkville, Victoria
  55. Parkville, Victoria
  56. Winnipeg, Manitoba
  57. Halifax, Nova Scotia
  58. London, Ontario
  59. Markham, Ontario
  60. Oakville, Ontario
  61. Peterborough, Ontario
  62. Sudbury, Ontario
  63. Sudbury, Ontario
  64. Toronto, Ontario
  65. Montreal, Quebec
  66. Quebec,
  67. Santiago, LAS Condes
  68. Santiago, Recoleta
  69. Santiago, Region Metropolitana
  70. Vina del Mar, Valparaiso
  71. Beijing, Beijing
  72. Beijing, Beijing
  73. Beijing, Beijing
  74. Guangzhou, Guangdong
  75. Shenzhen, Guangdong
  76. Wuhan, Hubei
  77. Nanjing, Jiangsu
  78. Shanghai, Shanghai
  79. Hangzhou, Zhejiang
  80. Hangzhou, Zhejiang
  81. Shanghai,
  82. Medellin, Antioquia
  83. Medellin, Antioquia
  84. Bogota, D.c.
  85. Brno,
  86. Brno,
  87. Nachod,
  88. Náchod,
  89. Olomouc,
  90. Praha 10,
  91. Praha 1,
  92. Praha 8 - Liben,
  93. Praha 8- Liben,
  94. Praha2,
  95. Bad Bentheim,
  96. Berlin,
  97. Erlangen,
  98. Frankfurt am Main,
  99. Luebeck,
  100. Luebeck,
  101. Muenster,
  102. Budapest,
  103. Debrecen,
  104. Gyongyos,
  105. Szeged,
  106. Nagoya, Aichi
  107. Sendai, Miyagi
  108. Hamamatsu, Shizuoka
  109. Koto-ku, Tokyo
  110. Shinjuku-ku, Tokyo
  111. Osaka,
  112. Busan,
  113. Seoul,
  114. Seoul,
  115. Veracruz,
  116. Krakow,
  117. Lodz,
  118. Szczecin,
  119. Warszawa,
  120. Warszawa,
  121. Wroclaw,
  122. Chelyabinsk,
  123. Kirov,
  124. Moscow,
  125. Moscow,
  126. Rostov-on-Don,
  127. Saint Petersburg,,
  128. Saint Petersburg,
  129. Saint Petersburg,
  130. Yaroslavl,
  131. Badalona, Barcelona
  132. Barcelona,
  133. Barcelona,
  134. Barcelona,
  135. Córdoba,
  136. Madrid,
  137. Madrid,
  138. Valencia,
  139. Kaohsiung City,
  140. Kaohsiung,
  141. New Taipei City,
  142. New Taipei City,
  143. Taichung,
  144. Taichung,
  145. Taipei,
  146. Taoyuan City,
  147. Brighton, EAST Sussex
  148. Southampton, Hampshire
  149. Dundee,
  150. Glasgow,
  151. Hampshire,
  152. London,
  153. London,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Long-Term PF-06651600 for the Treatment of Alopecia Areata
Official Title  ICMJE A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
Brief Summary

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.

A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Alopecia Areata
Intervention  ICMJE
  • Drug: PF-06651600
    50 mg oral tablets
  • Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
    Single subcutaneous injection administered to patients participating in the vaccine sub-study
  • Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
    Single subcutaneous injection administered to patients participating in the vaccine sub-study
Study Arms  ICMJE
  • Experimental: Treatment sequence 1

    Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 given QD for 23 months.

    Patients participating in the vaccine sub-study will receive the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 21 visit of the main B7981032 study.

    Interventions:
    • Drug: PF-06651600
    • Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
    • Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
  • Experimental: Treatment sequence 2

    Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 given QD for 24 months.

    Patients participating in the vaccine sub-study will receive the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 21 visit of the main B7981032 study.

    Interventions:
    • Drug: PF-06651600
    • Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
    • Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 14, 2020)		960
Original Estimated Enrollment  ICMJE
 (submitted: July 1, 2019)		860
Estimated Study Completion Date  ICMJE August 14, 2023
Estimated Primary Completion Date August 14, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria for de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:

  • Clinical diagnosis of alopecia areata (AA) with no other cause of hair loss. Androgenetic alopecia coexistent with AA is allowed.
  • >=25% terminal hair loss of the scalp due to AA, including alopecia totalis and alopecia universalis
  • No evidence of terminal scalp hair regrowth within 6 months
  • Current episode of terminal scalp hair loss <=10 years

Exclusion Criteria for de novo participants and participants from Study B7931005 and B7981015 with >30 days between first visit in B7981032 and last dose in the prior study:

  • Other types of diseases that can cause hair loss or that could interfere with assessment of hair loss/regrowth
  • Participants with shaved heads must not enter the study until hair has grown back & is considered stable by the investigator

All participants:

- Participants who have previously taken Janus kinase (JAK) inhibitors other than PF-06651600 must have received the last dose >12 weeks prior to the screening visit

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Argentina,   Australia,   Canada,   Chile,   Colombia,   Czechia,   Germany,   Hungary,   Japan,   Korea, Republic of,   Mexico,   Poland,   Russian Federation,   Spain,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04006457
Other Study ID Numbers  ICMJE B7981032
2019-001084-71 ( EudraCT Number )
ALLEGRO LT ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP